Business Context and Reporting Period
This Form 8-K was filed by Onconova Therapeutics, Inc. (ONTX) on December 10, 2019, reporting events occurring on December 6, 2019. The company is a biopharmaceutical firm focused on developing novel cancer therapies. The filing details a registered direct offering of common stock and warrants to institutional investors.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 14,326,648 shares of Common Stock and warrants to purchase 7,163,324 shares (Investor Warrants).
- Offering Price: $0.349 per share plus 0.5 Investor Warrant.
- Warrant Terms: Investor Warrants are exercisable immediately at $0.287 per share with a five-year term.
- Net Proceeds: Approximately $4.4 million after deducting placement agent fees and expenses.
- Additional Capital: Approximately $2.1 million in proceeds from the exercise of 10,443,000 common stock warrants since November 25, 2019.
- Outstanding Shares: Expected to be 86,717,110 shares as of December 10, 2019, assuming no further warrant exercises prior to closing.
Material Changes and Agreements
The company entered into definitive securities purchase agreements with institutional investors. Additionally, an Engagement Letter was signed with H.C. Wainwright & Co., LLC as the exclusive placement agent. The company agreed to pay Wainwright a 7.0% cash fee on gross proceeds, a 1.0% management fee, $85,000 for non-accountable expenses, and $10,000 for clearing fees. Wainwright also received Placement Agent Warrants to purchase 716,332 shares (5.0% of the offering) at an exercise price of $0.43625 per share.
Outlook, Risks, and Contingencies
Nasdaq Compliance: The offering is intended to ensure the company's stockholders' equity exceeds the $2.5 million minimum requirement for continued listing on The Nasdaq Capital Market (Rule 5550(b)(1)). The company intends to provide further information to Nasdaq to demonstrate long-term compliance.
Closing Conditions: The offering is expected to close on or about December 10, 2019, subject to customary closing conditions.
Future Capital Raises: The company granted Wainwright a twelve-month right of first refusal regarding additional fund raises and agreed to pay compensation if investors introduced by Wainwright participate in capital raises within eight months of the engagement's termination.
Investor Verification Checklist
- Verify the actual closing date and final net proceeds received from the registered direct offering.
- Confirm the company's receipt of the $2.1 million from recent warrant exercises.
- Monitor Nasdaq communications regarding the company's compliance with the $2.5 million stockholders' equity requirement.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific representations and warranties.
- Track the dilution impact of the 14.3 million new shares and 7.2 million investor warrants on existing shareholders.